Apoptosis Activators - Sarhan, Alaadin E.;El Sayed, Mardia T.
29,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
15 °P sammeln
  • Broschiertes Buch

Many impediments of current anti-cancer therapies have urged scientists to discover new agents. As a result of growing spectrums of new targets and strategies and recent biological and biotechnological progresses, many anti-cancer agents such as monoclonal antibodies, small molecule tyrosine kinase inhibitors, and epi-genetic drugs have reached clinical trials. This review helps to understand the rationale for the development of inhibitors against major targets such as cell growth, proliferation, survival, and angiogenesis and recent targets such as the proteasome, heat shock proteins, and…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Many impediments of current anti-cancer therapies have urged scientists to discover new agents. As a result of growing spectrums of new targets and strategies and recent biological and biotechnological progresses, many anti-cancer agents such as monoclonal antibodies, small molecule tyrosine kinase inhibitors, and epi-genetic drugs have reached clinical trials. This review helps to understand the rationale for the development of inhibitors against major targets such as cell growth, proliferation, survival, and angiogenesis and recent targets such as the proteasome, heat shock proteins, and epi-genetics. The book includes four chapters, beginning with the apoptosis definition, while the major classes of anti-cancer drugs are described in chapter two. Cancer growth blockers are briefly discussed in chapter three. Hence, chapter four provides an overview of important targets and design strategies to find treasure lead structures.
Autorenporträt
Dr. Alaadin E. Sarhan and Dr. Mardia T. El Sayed are Egyptian Associate Professors at the Industrial and Pharmaceutical Research Division at the National Research Center, Dokki, Egypt.